Aeglea BioTherapeutics reports Q1 2023 net loss of $18.4M; cash at $39.8M

Spyre Therapeutics, Inc.

2023-Q1 EPS reported -$0.20 revenue$198,000

Cash, equivalents, marketable securities, restricted cash totaled $39.8M as of March 31, 2023.
Revenue of $0.2M from Immedica Pharma license/supply agreement for pegzilarginase in Europe/Middle East.
R&D expenses fell to $13.8M from $17.0M; G&A expenses fell to $5.2M from $8.8M year-over-year.
Net loss improved to $18.4M from $24.4M in Q1 2022; includes $1.7M non-cash stock compensation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spyre Therapeutics, Inc. reported first quarter 2023 results: revenue $0.2 million, net income Net loss totaled $18.4 million.

Period: first quarter 2023
Revenue: $0.2 million
Net income: Net loss totaled $18.4 million
Result: reported results

Exact text from the filing

31, 2023, Aeglea had available cash and cash equivalents, marketable securities and restricted cash of $39.8 million. Aeglea recognized development fee and royalty revenues of $0.2 million in the first quarter of 2023, as a result of its license and supply agreement with Immedica Pharma AB for the commercial rights to pegzilarginase in Europe and several countries

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.